Allen & Co Inc/Allen Holding Inc, et al. – ‘SC 13D/A’ on 10/3/03 re: Regen Biologics Inc

On:  Friday, 10/3/03, at 4:51pm ET   ·   Accession #:  932799-3-175   ·   File #:  5-49089

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Amendment to General Statement of Beneficial Ownership   —   Schedule 13D
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: SC 13D/A    Amendment Ot Schedule 13D                              5     29K 
 4: EX-10       Ex10.1 Amended Stock Purchase Agreement               17±    68K 
 3: EX-10       Stockholder Purchase Agreements                        3     11K 
 2: EX-99       Exhibit 99.1                                           1      4K 

SC 13D/A   —   Amendment Ot Schedule 13D
Document Table of Contents

SC 13D/A
1st Page of 5
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

 Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 REGEN BIOLOGICS, INC.

(Name of Issuer)

 Common Stock, par value $0.01 per share

(Title of Class of Securities)

75884M 104

(CUSIP Number)

Rosemary Fanelli

Allen & Company Incorporated
711 Fifth Avenue
New York, NY 10022
(212) 832-8000

 (Name, Address and Telephone Number of Person
 Authorized to Receive Notices and Communications)

SC 13D/A
2nd Page of 5
TOC
1st
Previous
Next
↓Bottom
Just 2nd
                                                    September 16, 2003

 (Date of Event which Requires Filing of this Statement)

  If the filing person has previously filed a statement on Schedule 13G to
 report the acquisition that is the subject of this Schedule 13D, and is
  filing this schedule because of (paragraphs)240.13d-1 (e), 240.13d-1 (f)
or 240.13d-1 (g), check the following box.     [   ]                  

   Note: Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits.      
         See (paragraph)240.13d-7 for other parties to whom copies are to be
sent.                                                     

* The remainder of this cover page shall be filled out for a reporting
       person's initial filing on this form with respect to the subject class of
       securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.           

   The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities  
 Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
     that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).                                         

SC 13D/A
3rd Page of 5
TOC
1st
Previous
Next
↓Bottom
Just 3rd
CUSIP No. 75884M  104                                                           

             1.  Names of Reporting Persons. I.R.S. Identification Nos. of above
persons (entities only).                              
Allen & Company Incorporated                          
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------

2.  Check the Appropriate Box if a Member of a Group  
(See Instructions):                                   
(a)  [   ]                                            
(b)  [ x ]                                            
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------
3.  SEC Use Only                                      
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------
4.  Source of Funds (See Instructions):   WC          
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------
           5.  Check if Disclosure of Legal Proceedings Is Required Pursuant
to Items 2(d) or 2(e):                                

N/A                                                   
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------
6.  Citizenship or Place of Organization:             

New York                                              
------------------- ------------------------------------------------------------

Number of Shares                                                                
Beneficially                                                                    
Owned by Each                                                                   
Reporting Person    7.  Sole Voting Power:       2,901,220*                     
With                                                                            
                    ------------------------------------------------------------
                    ------------------------------------------------------------
8.  Shared Voting Power:             0  
                    ------------------------------------------------------------
                    ------------------------------------------------------------
9.  Sole Dispositive Power:  2,901,220* 
                    ------------------------------------------------------------
                    ------------------------------------------------------------
10.  Shared Dispositive Power:       0  
------------ -------------------------------------------------------------------
            11.  Aggregate Amount Beneficially Owned by Each Reporting Person:
                            2,901,220*
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------
         12.  Check if the Aggregate Amount in Row (11) Excludes Certain
Shares (See Instructions): [X]              

------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------
          13.  Percent of Class Represented by Amount in Row (11):   9.5%*
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------

14.  Type of Reporting Person (See Instructions):  CO 
------------ -------------------------------------------------------------------

SC 13D/A
4th Page of 5
TOC
1st
Previous
Next
↓Bottom
Just 4th
CUSIP No. 75884M  104                                                           
--------------------------------------------------------------------------------
------------ -------------------------------------------------------------------

             1.  Names of Reporting Persons. I.R.S. Identification Nos. of above
persons (entities only).                              
Allen Holding Inc.                                    
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------

2.  Check the Appropriate Box if a Member of a Group  
(See Instructions):                                   
(a)  [   ]                                            
(b)  [ x ]                                            
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------
3.  SEC Use Only                                      
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------
  4.  Source of Funds (See Instructions):   Not Applicable
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------
           5.  Check if Disclosure of Legal Proceedings Is Required Pursuant
to Items 2(d) or 2(e):                                

N/A                                                   
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------
6.  Citizenship or Place of Organization:             

Delaware                                              
------------------- ------------------------------------------------------------

Number of Shares                                                                
Beneficially                                                                    
Owned by Each                                                                   
Reporting Person    7.  Sole Voting Power:         0                            
With                                                                            
                    ------------------------------------------------------------
                    ------------------------------------------------------------
8.  Shared Voting Power:       0        
                    ------------------------------------------------------------
                    ------------------------------------------------------------
9.  Sole Dispositive Power:    0        
                    ------------------------------------------------------------
                    ------------------------------------------------------------
10.  Shared Dispositive Power: 0        
------------ -------------------------------------------------------------------
            11.  Aggregate Amount Beneficially Owned by Each Reporting Person:
                                 2,901,2201*
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------
         12.  Check if the Aggregate Amount in Row (11) Excludes Certain
Shares (See Instructions):                            
[X]                                                   
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------
          13.  Percent of Class Represented by Amount in Row (11):   9.5%*
------------ -------------------------------------------------------------------
------------ -------------------------------------------------------------------

14.  Type of Reporting Person (See Instructions):  HC 

------------ -------------------------------------------------------------------

Item 1.       Security and Issuer                                               

     This Amendment No. 1 to the statement on Schedule 13D relates to the common
stock,  par  value  $0.01  per  share,  of Regen  Biologics,  Inc.,  a  Delaware
corporation (the "Issuer"). The address of the principal executive office of the
Issuer is 1290 Bay Dale Drive, PMB 351, Arnold, MD 21012.                       

Item 3.       Source and Amount of Funds or Other Consideration                 

     Allen & Company Incorporated ("Allen") used working capital to purchase the
Acquired  Securities  (as  defined in Item 5(c)  hereof)  and paid the Issuer an
aggregate purchase price of $250,000 for the Acquired Securities:               

Item 4.       Purpose of Transaction                                            

     Allen  purchased the Acquired  Securities  for investment  purposes.  Allen
currently has no plans or proposals which would result in any actions  described
in clause (a) through (j) of Item 4 of the General  Instructions to the Schedule
13D.                                                                            

     In addition,  in connection with the a merger between the Aros  Corporation
and the Issuer on June 21, 2002, Allen, Dr. Richard Steadman,  M.D.,  Sanderling
Venture  Partners  IV  Co-Investment   Fund,  L.P.,   Sanderling  IV  Biomedical
Co-Investment Fund, L.P.,  Sanderling IV Venture Management,  Sanderling Venture
Partners V Co-Investment Fund, L.P., Sanderling V Biomedical Co-Investment Fund,
L.P., Sanderling V Limited Partnership, Sanderling V Beteiligungs GmbH & Co. KG,
Sanderling V Ventures  Management,  and  Centerpulse  USA Holding Co.  (formerly
Sulzer Medica Holding Co.),  all former  stockholders  of ReGen,  entered into a
Stockholders'  Agreement (the "Stockholders'  Agreement"),  dated as of June 21,
2002,  whereby the parties to the Stockholders'  Agreement agreed to vote all of
their  shares  of  capital  stock of the  Issuer in favor of  certain  corporate
actions,  including  but not  limited  to  maintaining  the  Issuer's  board  of
directors at seven (7) members,  electing  certain  individuals  to the Issuer's
board, amending the Issuer's certificate of incorporation to increase the number
of  authorized  shares of common  stock of the Issuer and  amending the Issuer's
by-laws.                                                                        

     As  previously  disclosed by Allen on a Form 4 relating to the Issuer filed
with the Securities Exchange Commission on December 23, 2002, the parties to the
Stockholders'  Agreement  on December  4, 2002,  executed  an  amendment  to the
Stockholders'  Agreement  (the  "Release")  pursuant to which the parties to the
Stockholders'   Agreement   released  Allen  from  its  obligations   under  the
Stockholders' Agreement, and as a consequence, Allen is no longer a party to the
Stockholders'  Agreement.  Under the terms of the Release which became effective
on November 26, 2002,  Allen,  as of the effective date, no longer shared voting
power or  dispositive  power of any of the Issuer's  securities  with any of the
parties to the Stockholders' Agreement.                                         

     References to and descriptions of the  Stockholders'  Agreement and Release
as set forth in this Item 4 are qualified in their  entirety by reference to the
copies of such agreements  included as Exhibits 3 and 4,  respectively,  to this
Amendment No. 1 to Schedule 13D, and are  incorporated in their entirety in this
Item 4.                                                                         

Item 5.       Interest in Securities of the Issuer                              

     (a)......As  of October 2, 2003,  Allen,  for purposes of Rule 13d-3 of the
Securities Exchange Act of 1934, as amended,  beneficially owns in the aggregate
2,901,220* shares of the Issuer's common stock (the "Shares"),  which represents
approximately  9.5% of the issued and outstanding  shares of the Issuer's common
stock (based on the number of shares reported to be outstanding by the Issuer in
its Form 10-Q dated August 14, 2003).                                           

     (b)......Allen  has the  sole  power to vote or to  direct  the vote and to
dispose or to direct the disposition of the Shares.                             

     (c)......Pursuant  to the Series C  Convertible  Preferred  Stock  Purchase
Agreement by and among the Issuer and certain investors,  including Allen, Allen
acquired for an aggregate  purchase  price of $250,000 (i) 557,911 shares of the
Issuer's  Series C  Convertible  Preferred  Stock and (ii)  warrants to purchase
52,163   shares  the  Issuer's   common  stock   (collectively,   the  "Acquired
Securities").                                                                   

(d) - (e)  Not applicable.                                    

Item 6.       Contracts, Arrangements, Understandings or Relationships with     
Respect to Securities of the Issuer                                             

     The transactions  effected by Allen pursuant to the Purchase  Agreement and
the Release are describe in Item 3 hereof.  The Purchase  Agreement  and Release
are being  filed as Exhibit 5 and 4,  respectively.  Except  for the  agreements
described in this Item 6, to the best of Allen's  knowledge,  there are no other
contracts,  arrangements,  understandings or relationships  (legal or otherwise)
between Allen and any persons with respect to any securities of the Issuer.     

Item 7.         Material to Be Filed as Exhibits.                               

Exhibit..           Description                               

1                   Officers and Directors of Allen & Company 
Incorporated          

2                   Agreement and Plan of Merger, dated as of 
          June 21, 2002, by and among Aros
                 Corporation, Aros Acquisition Corp. and
 ReGen Biologics, Inc.++

         3                   Stockholders' Agreement, dated as of June 21, 2002,
                     by and among the several stockholders named
therein.+             

       4                   Amendment to Stockholders' Agreement, dated as of
                     December 4, 2002 by and among Allen and the
             several stockholders named therein.

   5                   Series C Convertible Preferred Stock Purchase
                         Agreement by and among Regen Biologic, Inc. and
                      certain investors, including Allen & Company
Incorporated          

SC 13D/A
Last Page of 5
TOC
1st
Previous
Next
↓Bottom
Just 5th
 Signature

     After  reasonable  inquiry and to the best of my  knowledge  and belief,  I
certify that the information  set forth in this statement is true,  complete and
correct.                                                                        

Date:  October 2, 2003                                                          

Allen & Company Incorporated                                                    

By:      /s/ Rosemary Fanelli                                                   
--------------------                                          
Name:        Rosemary Fanelli                                 
         Title:       Vice President, Chief Administrative Officer and Secretary

Allen Holding Inc.                                                              

By:      /s/ Rosemary Fanelli                                                   
--------------------                                          
Name:        Rosemary Fanelli                                 
         Title:       Vice President, Chief Administrative Officer and Secretary

Footnotes:                                                                      
--------                                                                        

     *Includes 492,785 shares issuable upon the conversion of Series A Preferred
Stock,  557,911 shares  issuable upon the conversion of Series C Preferred Stock
and 335,289  shares  issuable  upon the  exercise of warrants.  Excludes  52,162
warrants  because these warrants are not currently  exercisable  within 60 days.
Allen  Holding  Inc.  owns  100% of the  outstanding  stock of  Allen &  Company
Incorporated  and so may be deemed to beneficially  own the shares which Allen &
Company Incorporated owns.                                                      

+ Incorporated herein by reference to the Schedule 13D filed by Allen on        
October 21, 2002.                                                               

++ Incorporated herein by  reference to Exhibit 10.1 of the 8-K filed by the    
Issuer on June 26, 2002                                                         

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘SC 13D/A’ Filing		Date		First		Last			Other Filings
Filed on:		10/3/03							3,  8-K,  SC 13G
		10/2/03		4		5
		9/16/03		2
		8/14/03		4					10-Q
		12/23/02		4					3,  4
		12/4/02		4
		11/26/02		4					4,  DEF 14A
		10/21/02		5					SC 13D
		6/26/02		5					8-K
		6/21/02		4					3,  8-K
									List all Filings